Technology | July 01, 2009

Gore Receives FDA Clearance for Modified GORE VIABAHN Endoprosthesis

July 1, 2009 – W. L. Gore & Associates said today it received FDA for a manufacturing change to the GORE VIABAHN Endoprosthesis, which is a result of the precision laser trimming technology that enables the removal of excess material at the device margin, resulting in a contoured edge.

The device is the only stent graft approved by the FDA for the treatment of patients suffering from peripheral arterial disease (PAD) in superficial femoral artery (SFA) lesions and iliac artery lesions. In the U.S. alone, as many as 12 million people suffer from PAD.

“I commonly use the GORE VIABAHN Device in my practice for treatment of patients with complex SFA lesions,” said Darren B. Schneider, M.D., associate professor of vascular surgery and radiology at the University of California, San Francisco. “My hope is that the laser contoured edge at the proximal end may improve flow dynamics of blood entering the endoprosthesis.”

The GORE VIABAHN Endoprosthesis is constructed with a durable, reinforced, biocompatible, expanded polytetrafluoroethylene (ePTFE) liner attached to an external nitinol stent structure. The outstanding flexibility of the GORE VIABAHN Endoprothesis enables it to traverse tortuous areas of the SFA and conform to the complex anatomy of the artery. The FDA initially approved the device in 2005 for treating PAD in the SFA. Later in 2007, Gore made modifications, which include reducing the profile and adding a heparin bioactive surface.

GORE VIABAHN Endoprosthesis is indicated for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery lesions with reference diameters ranging from 4 mm to 7.5 mm. The GORE VIABAHN Endoprosthesis is indicated for improving blood flow with symptomatic peripheral arterial disease in the iliac artery lesions with reference vessel diameters from 4 mm to 12 mm.

For more information:

Related Content

Aortic Stent Graft Global Market to Reach $5.4 Billion by 2028
News | Stent Grafts | February 14, 2019
Abdominal aortic stent grafts will remain the largest segment in the global aortic stent graft market at least through...
Medtronic Receives FDA Approval for Valiant Navion Thoracic Stent Graft System
Technology | Stent Grafts | February 07, 2019
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for the Valiant Navion thoracic stent...
Endologix Ends Unrestricted Sales and Use of Nellix System
News | Stent Grafts | January 07, 2019
January 7, 2019 — Endologix Inc.
Endologix Reports Positive One-Year Results From the Ovation LUCY Study
News | Stent Grafts | July 16, 2018
Endologix Inc. announced one-year results from the LUCY (Evaluation of FemaLes who are Underrepresented Candidates for...
FDA Committee Votes in Favor of Incraft AAA Stent Graft System
News | Stent Grafts | June 13, 2018
Cardinal Health announced that its Incraft Abdominal Aortic Aneurysm (AAA) Stent Graft System has received a favorable...
First Patient Enrolled in Gore Excluder Investigational Study
News | Stent Grafts | January 08, 2018
January 8, 2018 — W. L. Gore & Associates Inc.
FDA Concerned About Increase in stent graft Endovascular Type III Leaks
News | Stent Grafts | October 09, 2017
October 9, 2017 — The U.S.
Gore Announces First-in-Human Use of Gore TAG Conformable Thoracic Stent Graft
News | Stent Grafts | July 17, 2017
W. L. Gore & Associates Inc. announced the first patient implant of the Gore TAG Conformable Thoracic Stent Graft...
News | Stent Grafts | April 06, 2017
Endologix Inc. announced that the first patients were treated in the Expanding Patient Applicability with Polymer...
Gore, Viabahn VBX Balloon Expandable Endoprosthesis, stent graft, iliac artery, FDA approval
Technology | Stent Grafts | January 31, 2017
W. L. Gore & Associates (Gore) announced that the Gore Viabahn VBX Balloon Expandable Endoprosthesis (VBX Stent...
Overlay Init